Is Monitoring Mean Platelet Volume Necessary in Breast Cancer Patients?

Halil Taskaynatan, Ahmet Alacacioglu, Yuksel Kucukzeybek, Umut Varol, Yasar Yildiz, Tarik Salman, Utku Oflazoglu, Mustafa Oktay Tarhan, Halil Taskaynatan, Ahmet Alacacioglu, Yuksel Kucukzeybek, Umut Varol, Yasar Yildiz, Tarik Salman, Utku Oflazoglu, Mustafa Oktay Tarhan

Abstract

Background: Mean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy.

Methods: Data of 261 patients who had pathologically confirmed estrogen or progesterone receptor positive invasive breast cancer and had received hormonotherapy for at least a 5-year period were retrospectively analyzed. MPV levels were measured at baseline and at the first and fifth year of hormone therapy.

Results: All patients were females and their median age was 50 years (range, 27-78 years). The mean MPV value was significantly increased in all patients in the Tmx, AI, and switch groups over time (p<0.001).

Conclusion: This is the first study evaluating the relationship between the 5-year adjuvant endocrine therapy and changes in MPV values in breast cancer patients. Monitoring changes in MPV values may be predictive for severe side effects in breast cancer patients receiving hormone therapy.

Keywords: Aromatase inhibitors; Breast cancer; Mean platelet volume; Side effect; Tamoxifen.

Conflict of interest statement

Conflict of interest Conflict of interest statement: Authors state no conflict of interest

Figures

Figure 1A
Figure 1A
Mean platelet volume (MPV) at baseline and at the first and fifth years of hormone therapy in all patients
Figure 1B
Figure 1B
Mean platelet volume (MPV) at baseline and at the first and fifth years of hormone therapy in the study groups

References

    1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61. –.
    1. Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Pereu CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;31:203. –.
    1. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H.-J. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206. –.
    1. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the “ArimidexTM and tamoxifen alone or in combination” (ATAC) trial. Br J Cancer. 2001;85:317. –.
    1. Mangalpally KKR, Siqueiros-Garcia A, Vaduganathan M, Dong JF, Kleiman NS, Guthikonda S. Platelet activation patterns in platelet size sub-populations: Differential responses to aspirin in vitro. J Thromb Thrombolysis. 2010;30:251. –.
    1. Rabbani LRE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis. 1994;105:1. –.
    1. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. The New England Journal of Medicine. 1986;315:983. –.
    1. Kim SJ, Jenne CN. Role of platelets in neutrophil extracellular trap (NET) production and tissue injury. Semin Immunol. 2016;28:546. –.
    1. Karpatkin S.. Heterogeneity of human platelets. J Clin Invest. 1969;48:1083. –.
    1. Kamath S, Blann AD, Lip GYH. Platelet activation: Assessment and quantification. Eur Heart J. 2001;22:1561. –.
    1. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409. –.
    1. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399. –.
    1. D’erasmo E, Alıbertı G, Celı FS, Romagnolı E, Veccı E, Mazzuolı GF. Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. J Intern Med. 1990;227:11. –.
    1. Senaran H, Ileri M, Altinbas A, Kosar A, Yetkin E, Ozturk M, Karaaslan Y, Kirazlı S. Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol. 2001;24:405. –.
    1. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451. Early Breast Cancer Trialists Collaborative Group. –.
    1. Cutuli B, Petit J, Fricker J, Jung G, Schumacher C, Velten M, Abecassis J. Adjuvant tamoxifen in breast-cancer-treatment in postmenopausal women - occurrence of thromboembolic complications. Oncol Rep. 1994;1:59. –.
    1. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608. –.
    1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 2011;378:771. Early Breast Cancer Trialists Collaborative Group. –.
    1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652. –.
    1. Howell PA. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60. –.
    1. Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, Tarantini L, Gori S. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clin Breast Cancer. 2017;17:11. –.
    1. Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast. 2016;26:106. –.
    1. Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast. 2010;19:76. –.
    1. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI J Natl Cancer Inst. 2011;103:1299. –.
    1. Karagoz B, Bilgi O, Alacacioglu A, Ozgun A, Sayan O, Erikci AA, Kandemir EG. Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer. Med Oncol. 2010;27:199. –.
    1. Brækkan SK, Mathiesen EB, NjøLstad I, Wilsgaard T, StøRmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: The TromsØ study. J Thromb Haemost. 2010;8:157. –.
    1. Chu S, Becker R. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis. J Thromb Haemost. 2010;8:148. –.
    1. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805. For the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. –.
    1. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castigli-one-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715. –.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅